▶ 調査レポート

神経因性排尿筋過活動(NDO)の世界市場見通し2023年-2029年

• 英文タイトル:Neurogenic Detrusor Overactivity(NDO) Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。神経因性排尿筋過活動(NDO)の世界市場見通し2023年-2029年 / Neurogenic Detrusor Overactivity(NDO) Market, Global Outlook and Forecast 2023-2029 / MRC2312MG05335資料のイメージです。• レポートコード:MRC2312MG05335
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、85ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥487,500 (USD3,250)▷ お問い合わせ
  Enterprise User¥731,250 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界の神経因性排尿筋過活動(NDO)市場規模と予測を収録しています。・世界の神経因性排尿筋過活動(NDO)市場:売上、2018年-2023年、2024年-2029年
・世界の神経因性排尿筋過活動(NDO)市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の神経因性排尿筋過活動(NDO)市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「非外科的治療」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

神経因性排尿筋過活動(NDO)のグローバル主要企業は、Astellas Pharma、 AbbVie、 Medtronicなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、神経因性排尿筋過活動(NDO)のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の神経因性排尿筋過活動(NDO)市場:タイプ別、2018年-2023年、2024年-2029年
世界の神経因性排尿筋過活動(NDO)市場:タイプ別市場シェア、2022年
・非外科的治療、外科的治療、経過観察治療

世界の神経因性排尿筋過活動(NDO)市場:用途別、2018年-2023年、2024年-2029年
世界の神経因性排尿筋過活動(NDO)市場:用途別市場シェア、2022年
・大人、子供

世界の神経因性排尿筋過活動(NDO)市場:地域・国別、2018年-2023年、2024年-2029年
世界の神経因性排尿筋過活動(NDO)市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における神経因性排尿筋過活動(NDO)のグローバル売上、2018年-2023年
・主要企業における神経因性排尿筋過活動(NDO)のグローバル売上シェア、2022年
・主要企業における神経因性排尿筋過活動(NDO)のグローバル販売量、2018年-2023年
・主要企業における神経因性排尿筋過活動(NDO)のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Astellas Pharma、 AbbVie、 Medtronic

*************************************************************

・調査・分析レポートの概要
神経因性排尿筋過活動(NDO)市場の定義
市場セグメント
世界の神経因性排尿筋過活動(NDO)市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の神経因性排尿筋過活動(NDO)市場規模
世界の神経因性排尿筋過活動(NDO)市場規模:2022年 VS 2029年
世界の神経因性排尿筋過活動(NDO)市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの神経因性排尿筋過活動(NDO)の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の神経因性排尿筋過活動(NDO)製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:非外科的治療、外科的治療、経過観察治療
神経因性排尿筋過活動(NDO)のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:大人、子供
神経因性排尿筋過活動(NDO)の用途別グローバル売上・予測

・地域別市場分析
地域別神経因性排尿筋過活動(NDO)市場規模 2022年と2029年
地域別神経因性排尿筋過活動(NDO)売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Astellas Pharma、 AbbVie、 Medtronic
...

This research report provides a comprehensive analysis of the Neurogenic Detrusor Overactivity(NDO) market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Neurogenic Detrusor Overactivity(NDO) market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Neurogenic Detrusor Overactivity(NDO), challenges faced by the industry, and potential opportunities for market players.
The global Neurogenic Detrusor Overactivity(NDO) market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Neurogenic Detrusor Overactivity(NDO) market presents opportunities for various stakeholders, including Aldult, Child. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Neurogenic Detrusor Overactivity(NDO) market. Additionally, the growing consumer demand present avenues for market expansion.
The global Neurogenic Detrusor Overactivity(NDO) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Neurogenic Detrusor Overactivity(NDO) market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Neurogenic Detrusor Overactivity(NDO) market.
Market Overview: The report provides a comprehensive overview of the Neurogenic Detrusor Overactivity(NDO) market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Non-surgical Treatment, Surgical Treatment), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Neurogenic Detrusor Overactivity(NDO) market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Neurogenic Detrusor Overactivity(NDO) market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Neurogenic Detrusor Overactivity(NDO) market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Neurogenic Detrusor Overactivity(NDO) market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Neurogenic Detrusor Overactivity(NDO) market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Neurogenic Detrusor Overactivity(NDO) market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Neurogenic Detrusor Overactivity(NDO), including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Neurogenic Detrusor Overactivity(NDO) market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Neurogenic Detrusor Overactivity(NDO) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Non-surgical Treatment
Surgical Treatment
Follow-up Treatment
Market segment by Application
Aldult
Child
Global Neurogenic Detrusor Overactivity(NDO) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Astellas Pharma
AbbVie
Medtronic
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neurogenic Detrusor Overactivity(NDO), market overview.
Chapter 2: Global Neurogenic Detrusor Overactivity(NDO) market size in revenue and volume.
Chapter 3: Detailed analysis of Neurogenic Detrusor Overactivity(NDO) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurogenic Detrusor Overactivity(NDO) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neurogenic Detrusor Overactivity(NDO) capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Neurogenic Detrusor Overactivity(NDO) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neurogenic Detrusor Overactivity(NDO) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neurogenic Detrusor Overactivity(NDO) Overall Market Size
2.1 Global Neurogenic Detrusor Overactivity(NDO) Market Size: 2022 VS 2029
2.2 Global Neurogenic Detrusor Overactivity(NDO) Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Neurogenic Detrusor Overactivity(NDO) Sales: 2018-2029
3 Company Landscape
3.1 Top Neurogenic Detrusor Overactivity(NDO) Players in Global Market
3.2 Top Global Neurogenic Detrusor Overactivity(NDO) Companies Ranked by Revenue
3.3 Global Neurogenic Detrusor Overactivity(NDO) Revenue by Companies
3.4 Global Neurogenic Detrusor Overactivity(NDO) Sales by Companies
3.5 Global Neurogenic Detrusor Overactivity(NDO) Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Neurogenic Detrusor Overactivity(NDO) Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Neurogenic Detrusor Overactivity(NDO) Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neurogenic Detrusor Overactivity(NDO) Players in Global Market
3.8.1 List of Global Tier 1 Neurogenic Detrusor Overactivity(NDO) Companies
3.8.2 List of Global Tier 2 and Tier 3 Neurogenic Detrusor Overactivity(NDO) Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Neurogenic Detrusor Overactivity(NDO) Market Size Markets, 2022 & 2029
4.1.2 Non-surgical Treatment
4.1.3 Surgical Treatment
4.1.4 Follow-up Treatment
4.2 By Type – Global Neurogenic Detrusor Overactivity(NDO) Revenue & Forecasts
4.2.1 By Type – Global Neurogenic Detrusor Overactivity(NDO) Revenue, 2018-2023
4.2.2 By Type – Global Neurogenic Detrusor Overactivity(NDO) Revenue, 2024-2029
4.2.3 By Type – Global Neurogenic Detrusor Overactivity(NDO) Revenue Market Share, 2018-2029
4.3 By Type – Global Neurogenic Detrusor Overactivity(NDO) Sales & Forecasts
4.3.1 By Type – Global Neurogenic Detrusor Overactivity(NDO) Sales, 2018-2023
4.3.2 By Type – Global Neurogenic Detrusor Overactivity(NDO) Sales, 2024-2029
4.3.3 By Type – Global Neurogenic Detrusor Overactivity(NDO) Sales Market Share, 2018-2029
4.4 By Type – Global Neurogenic Detrusor Overactivity(NDO) Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Neurogenic Detrusor Overactivity(NDO) Market Size, 2022 & 2029
5.1.2 Aldult
5.1.3 Child
5.2 By Application – Global Neurogenic Detrusor Overactivity(NDO) Revenue & Forecasts
5.2.1 By Application – Global Neurogenic Detrusor Overactivity(NDO) Revenue, 2018-2023
5.2.2 By Application – Global Neurogenic Detrusor Overactivity(NDO) Revenue, 2024-2029
5.2.3 By Application – Global Neurogenic Detrusor Overactivity(NDO) Revenue Market Share, 2018-2029
5.3 By Application – Global Neurogenic Detrusor Overactivity(NDO) Sales & Forecasts
5.3.1 By Application – Global Neurogenic Detrusor Overactivity(NDO) Sales, 2018-2023
5.3.2 By Application – Global Neurogenic Detrusor Overactivity(NDO) Sales, 2024-2029
5.3.3 By Application – Global Neurogenic Detrusor Overactivity(NDO) Sales Market Share, 2018-2029
5.4 By Application – Global Neurogenic Detrusor Overactivity(NDO) Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Neurogenic Detrusor Overactivity(NDO) Market Size, 2022 & 2029
6.2 By Region – Global Neurogenic Detrusor Overactivity(NDO) Revenue & Forecasts
6.2.1 By Region – Global Neurogenic Detrusor Overactivity(NDO) Revenue, 2018-2023
6.2.2 By Region – Global Neurogenic Detrusor Overactivity(NDO) Revenue, 2024-2029
6.2.3 By Region – Global Neurogenic Detrusor Overactivity(NDO) Revenue Market Share, 2018-2029
6.3 By Region – Global Neurogenic Detrusor Overactivity(NDO) Sales & Forecasts
6.3.1 By Region – Global Neurogenic Detrusor Overactivity(NDO) Sales, 2018-2023
6.3.2 By Region – Global Neurogenic Detrusor Overactivity(NDO) Sales, 2024-2029
6.3.3 By Region – Global Neurogenic Detrusor Overactivity(NDO) Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Neurogenic Detrusor Overactivity(NDO) Revenue, 2018-2029
6.4.2 By Country – North America Neurogenic Detrusor Overactivity(NDO) Sales, 2018-2029
6.4.3 US Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.4.4 Canada Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.4.5 Mexico Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Neurogenic Detrusor Overactivity(NDO) Revenue, 2018-2029
6.5.2 By Country – Europe Neurogenic Detrusor Overactivity(NDO) Sales, 2018-2029
6.5.3 Germany Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.5.4 France Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.5.5 U.K. Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.5.6 Italy Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.5.7 Russia Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.5.8 Nordic Countries Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.5.9 Benelux Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Neurogenic Detrusor Overactivity(NDO) Revenue, 2018-2029
6.6.2 By Region – Asia Neurogenic Detrusor Overactivity(NDO) Sales, 2018-2029
6.6.3 China Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.6.4 Japan Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.6.5 South Korea Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.6.6 Southeast Asia Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.6.7 India Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Neurogenic Detrusor Overactivity(NDO) Revenue, 2018-2029
6.7.2 By Country – South America Neurogenic Detrusor Overactivity(NDO) Sales, 2018-2029
6.7.3 Brazil Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.7.4 Argentina Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Neurogenic Detrusor Overactivity(NDO) Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Neurogenic Detrusor Overactivity(NDO) Sales, 2018-2029
6.8.3 Turkey Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.8.4 Israel Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.8.5 Saudi Arabia Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
6.8.6 UAE Neurogenic Detrusor Overactivity(NDO) Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Astellas Pharma
7.1.1 Astellas Pharma Company Summary
7.1.2 Astellas Pharma Business Overview
7.1.3 Astellas Pharma Neurogenic Detrusor Overactivity(NDO) Major Product Offerings
7.1.4 Astellas Pharma Neurogenic Detrusor Overactivity(NDO) Sales and Revenue in Global (2018-2023)
7.1.5 Astellas Pharma Key News & Latest Developments
7.2 AbbVie
7.2.1 AbbVie Company Summary
7.2.2 AbbVie Business Overview
7.2.3 AbbVie Neurogenic Detrusor Overactivity(NDO) Major Product Offerings
7.2.4 AbbVie Neurogenic Detrusor Overactivity(NDO) Sales and Revenue in Global (2018-2023)
7.2.5 AbbVie Key News & Latest Developments
7.3 Medtronic
7.3.1 Medtronic Company Summary
7.3.2 Medtronic Business Overview
7.3.3 Medtronic Neurogenic Detrusor Overactivity(NDO) Major Product Offerings
7.3.4 Medtronic Neurogenic Detrusor Overactivity(NDO) Sales and Revenue in Global (2018-2023)
7.3.5 Medtronic Key News & Latest Developments
8 Global Neurogenic Detrusor Overactivity(NDO) Production Capacity, Analysis
8.1 Global Neurogenic Detrusor Overactivity(NDO) Production Capacity, 2018-2029
8.2 Neurogenic Detrusor Overactivity(NDO) Production Capacity of Key Manufacturers in Global Market
8.3 Global Neurogenic Detrusor Overactivity(NDO) Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neurogenic Detrusor Overactivity(NDO) Supply Chain Analysis
10.1 Neurogenic Detrusor Overactivity(NDO) Industry Value Chain
10.2 Neurogenic Detrusor Overactivity(NDO) Upstream Market
10.3 Neurogenic Detrusor Overactivity(NDO) Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neurogenic Detrusor Overactivity(NDO) Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer